Nimotuzumab is a humanized IgG1 monoclonal antibody engineered to target the epidermal growth factor receptor (EGFR) with a dissociation constant (K_D) of 0.21 nM. This antibody specifically binds to the extracellular domain of EGFR, effectively inhibiting the receptor's interaction with its natural ligands. Nimotuzumab exhibits potent antitumor activity, primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism facilitates the targeted destruction of tumor cells, underscoring its utility in oncological research and therapeutic applications.
Nimotuzumab is a humanized IgG1 monoclonal antibody engineered to target the epidermal growth factor receptor (EGFR) with a dissociation constant (K_D) of 0.21 nM. This antibody specifically binds to the extracellular domain of EGFR, effectively inhibiting the receptor's interaction with its natural ligands. Nimotuzumab exhibits potent antitumor activity, primarily through the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This mechanism facilitates the targeted destruction of tumor cells, underscoring its utility in oncological research and therapeutic applications.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
